Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and LMP-specific T-cells in Pediatric EBV+ PTLD
NCT02900976Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2017
- Primary completion
- Mar 2021
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Children's Oncology Group. Started Mar 2017; status: completed.
02
Drugs
allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT02900976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900976.